Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors
© 2021. The Author(s), under exclusive licence to CPS and SIMM..
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are regarded as 'incretins' working closely to regulate glucose homeostasis. Unimolecular dual and triple agonists of GLP-1R and GIPR have shown remarkable clinical benefits in treating type 2 diabetes. However, their pharmacological characterization is usually carried out in a single receptor-expressing system. In the present study we constructed a co-expression system of both GLP-1R and GIPR to study the signaling profiles elicited by mono, dual and triple agonists. We show that when the two receptors were co-expressed in HEK 293T cells with comparable receptor ratio to pancreatic cancer cells, GIP predominately induced cAMP accumulation while GLP-1 was biased towards β-arrestin 2 recruitment. The presence of GIPR negatively impacted GLP-1R-mediated cAMP and β-arrestin 2 responses. While sharing some common modulating features, dual agonists (peptide 19 and LY3298176) and a triple agonist displayed differentiated signaling profiles as well as negative impact on the heteromerization that may help interpret their superior clinical efficacies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Acta pharmacologica Sinica - 43(2022), 6 vom: 26. Juni, Seite 1453-1460 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yu-Zhe [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.06.2022 Date Revised 02.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41401-021-00758-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329897497 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329897497 | ||
| 003 | DE-627 | ||
| 005 | 20231225210123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41401-021-00758-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329897497 | ||
| 035 | |a (NLM)34446852 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yu-Zhe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2022 | ||
| 500 | |a Date Revised 02.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to CPS and SIMM. | ||
| 520 | |a Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are regarded as 'incretins' working closely to regulate glucose homeostasis. Unimolecular dual and triple agonists of GLP-1R and GIPR have shown remarkable clinical benefits in treating type 2 diabetes. However, their pharmacological characterization is usually carried out in a single receptor-expressing system. In the present study we constructed a co-expression system of both GLP-1R and GIPR to study the signaling profiles elicited by mono, dual and triple agonists. We show that when the two receptors were co-expressed in HEK 293T cells with comparable receptor ratio to pancreatic cancer cells, GIP predominately induced cAMP accumulation while GLP-1 was biased towards β-arrestin 2 recruitment. The presence of GIPR negatively impacted GLP-1R-mediated cAMP and β-arrestin 2 responses. While sharing some common modulating features, dual agonists (peptide 19 and LY3298176) and a triple agonist displayed differentiated signaling profiles as well as negative impact on the heteromerization that may help interpret their superior clinical efficacies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LY3298176 | |
| 650 | 4 | |a glucagon-like peptide-1 receptor | |
| 650 | 4 | |a glucose-dependent insulinotropic peptide receptor | |
| 650 | 4 | |a heteromerization | |
| 650 | 4 | |a peptide 19 | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a beta-Arrestin 2 |2 NLM | |
| 650 | 7 | |a Gastric Inhibitory Polypeptide |2 NLM | |
| 650 | 7 | |a 59392-49-3 |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Yang, De-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ming-Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmacologica Sinica |d 2000 |g 43(2022), 6 vom: 26. Juni, Seite 1453-1460 |w (DE-627)NLM111735181 |x 1745-7254 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:6 |g day:26 |g month:06 |g pages:1453-1460 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41401-021-00758-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 6 |b 26 |c 06 |h 1453-1460 | ||